

Appendix 1. Maternal Characteristics Between Study Participants and Excluded Patients

	Participants (n=187)	Excluded patients (n=57)	p
Age (years)	31.8±0.3	31.44±0.6	0.16
Ethnic origin			
Caucasian	102/187 (55)	36/57 (63)	0.25
African-French Antilles	44/187 (24)	12/57 (21)	0.69
Northern African	34/187 (18)	8/57 (14)	0.46
Asian	7/187 (4)	1/57 (2)	
BMI (kg/m ²)	25.9±0.4	25.9±0.5	0.98
Gravidity	2 [2 ; 3]	2 [2 ; 4]	0.77
Parity	1 [1 ; 2]	1 [1 ; 2]	0.90
Chronic hypertension	34/187 (18)	13/57 (23)	0.43
Pre-existing diabetes	4/187 (2)	1/57 (2)	
Nephropathy	3/187 (2)	0	
Autoimmune disease	8/187 (4)	0	
Obstetric history			
Preeclampsia <34 wk	187/187 (100)	57/57 (100)	
HELLP syndrome	47/187 (25)	14/57 (25)	
SGA <10 th percentile	124/187 (66)	39/57 (68)	
Baseline blood pressure (mm Hg)			
Systolic mean±SD	121±13	121±19	0.71
Diastolic mean±SD	74±10	72±13	0.37
Aspirin group	94/187 (50)	28/57 (49)	0.87
LMWH + Aspirin group	93/187 (50)	29/57 (51)	0.87
Composite outcome	71/187 (38)	21/57 (37)	0.88
Preeclampsia	35/187 (19)	14/57 (25)	0.33
Abruption	4/187 (2)	02/57 (4)	
Perinatal death	4/187 (2)	01/57 (2)	
SGA <10 th percentile	46/187 (25)	13/57 (23)	0.78
SGA <5 th percentile	28/187 (15)	10/57 (18)	0.63

LMWH, low-molecular-weight heparin; BMI, body mass index; HELLP, hemolysis elevated liver enzymes and low platelet count; SGA, small for gestational age. Data are mean±SD, n/N (%).or median (interquartile range, quartile 1–3).

Lecarpentier E, Gris JC, Cochery-Nouvellon E, Mercier E, Abbas H, Thadhani R, et al. Urinary placental growth factor for prediction of placental adverse outcomes in high-risk pregnancies. *Obstet Gynecol* 2019;134.

The authors provided this information as a supplement to their article.

©2019 American College of Obstetricians and Gynecologists.

Page 1 of 3

Appendix 2. Concentrations of Urinary PIGF/Creatinine (pg/mg) Throughout Pregnancy

Gestational age in weeks	Urinary PIGF/Creat						p
	No composite adverse outcome (n=116)			Composite adverse outcome <34 wk (n=25)			
	Median [IQ]	Mean ± SEM	Samples (n=)	Median [IQ]	Mean ± SEM	Samples (n=)	
10- 13+6/7	52.0 [35.0;81.7]	87.7±17.5	90	34.1 [22.6;67.9]	49.7±8.3	22	0.06
14- - 17+6/7	80.6 [51.7;134.1]	114.4±14.2	107	65.0 [37.7;120.2]	89.4±17.2	24	0.25
18 - 21+6/7	176. [90.1;305.0]	321.8±148.5	15	39.0 [25.3;127.3]	68.8±27.8	5	<0.05
22- 25+6/7	255.6 [118.7;391.8]	312.9±25.4	99	42.7 [32.4;80.8]	56.9±7.8	19	< 0.0001
26 - 29+6/7	347.6 [175.4;551.8]	432.3±50.6	95	34.5 [18.7;51.0]	43.4±12.4	17	< 0.0001
30 - 33+6/7	297.2 [128.8;579.3]	390.5±31.7	103	75.6 [38.2;111.3]	75.0±19.2	4	<0.05
34 - 37+6/7	135.7 [65.2;310.9]	266.5±45.8	88				

Comparison between normal pregnancy group and group that developed composite adverse outcomes <34 weeks.

Appendix 3. Concentrations of Urinary PIGF/Creatinine (pg/mg) Throughout Pregnancy

Gestation age in (weeks)	Urinary PIGF/Creat						p
	No preeclampsia (n=152)			Preeclampsia at less than 34 wk (n=16)			
	Median [IQ]	Mean ± SEM	Samples (n=)	Median [IQ]	Mean ± SEM	Samples (n=)	
10 - 13+6/6	51.2 [32.4;77.8]	79.23±13.59	117	39.4 [26.9;69.6]	53.97±11.27	14	0.28
14 - 17+6/7	77.4 [51.7;126.0]	108.9±11.44	138	69.1 [42.6;95.3]	77.02±11.01	17	0.36
18 - 21+6/7	141.2 [75.1;245.9]	241.6±90.83	25	32.8 [26.5;39.1]	32.81±6.28	2	<0.05
22 - 25+6/7	244.6 [112.9;390.6]	294.8±21.02	128	42.7 [27.5;80.8]	54.07±7.737	15	< 0.0001
26 - 29+6/7	298.7 [157.8;522.5]	406±44.48	125	34.7 [18.1;43.6]	31.53±4.756	12	< 0.0001
30 - 33+6/7	264.3 [113.2;565.8]	364.7±28.18	128	52.5 [33.4;98.7]	61.54±19.37	3	<0.05
34 - 37+6/7	129.1 [56.4;282.9]	259.4±40.66	112				

Comparison between group with no preeclampsia and group that developed preeclampsia <34 weeks.